EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Dualistic Effects of PRKAR1A as a Potential Anticancer Target in Cancer Cells and Cancer-Derived Stem Cells

Joong-Won Baek, A-Reum Nam, Kyunggon Kim iD, Pyung-Hwan Kim iD

International Journal of Molecular Sciences · 2024

DOI: 10.3390/ijms25052876 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2024. Verfasst von Joong-Won Baek und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biomedical Laboratory Science, Konyang University, Daejeon 35365, Republic of Korea. Hauptthemen laut MEDLINE: Antineoplastic Agents, Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Research Foundation of Korea (NRF).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The integration of innovative medical technologies and interdisciplinary collaboration could improve the treatment of cancer, a globally prevalent and often deadly disease. Despite recent advancements, current cancer therapies fail to specifically address recurrence and target cancer stem cells (CSCs), which contribute to relapse. In this study, we utilized three types of cancer cells, from which three types of CSCs were further derived, to conduct a proteomic analysis. Additionally, shared cell surface biomarkers were identified as potential targets for a comprehensive treatment strategy. The selected biomarkers were evaluated through short hairpin RNA treatment, which revealed contrasting functions in cancer cells and CSCs. Knockdown of the identified proteins revealed that they regulate the epithelial–mesenchymal transition (EMT) and stemness via the ERK signaling pathway. Resistance to anticancer agents was consequently reduced, ultimately enhancing the overall anticancer effects of the treatment. Additionally, the significance of these biomarkers in clinical patient outcomes was confirmed using bioinformatics. Our study suggests a novel cancer treatment strategy that addresses the limitations of current anticancer therapies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic AgentsNeoplasmsHumansCell Line, TumorProteomicsBiomarkersTranscription FactorsNeoplastic Stem CellsEpithelial-Mesenchymal TransitionCyclic AMP-Dependent Protein Kinase RIalpha Subunit

Stichwörter der Autor:innen

cancercancer stem cellsdualistic effectnew biomarkersproteomic analysis

Substanzen

Antineoplastic AgentsBiomarkersTranscription FactorsPRKAR1A protein, humanCyclic AMP-Dependent Protein Kinase RIalpha Subunit

Autor:innen und Institutionen

  • Department of Biomedical Laboratory Science, Konyang University, Daejeon 35365, Republic of Korea.
  • Department of Veterinary Medicine, Seoul National University, Seoul 08826, Republic of Korea.
  • Department of Convergence Medicine, Asan Medical Center, Seoul 05505, Republic of Korea.

ORCID-Profile: Kyunggon Kim, Pyung-Hwan Kim

Förderung

  • National Research Foundation of Korea (NRF)

Zitieren

APA

Baek, J. W., Nam, A. R., Kim, K., & Kim, P. H. (2024). Dualistic Effects of PRKAR1A as a Potential Anticancer Target in Cancer Cells and Cancer-Derived Stem Cells. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms25052876

Vancouver

Baek JW, Nam AR, Kim K, Kim PH. Dualistic Effects of PRKAR1A as a Potential Anticancer Target in Cancer Cells and Cancer-Derived Stem Cells. International Journal of Molecular Sciences. 2024. doi:10.3390/ijms25052876

BibTeX
@article{Baek2024,
  author = {Baek, Joong-Won and Nam, A-Reum and Kim, Kyunggon and Kim, Pyung-Hwan},
  title = {Dualistic Effects of PRKAR1A as a Potential Anticancer Target in Cancer Cells and Cancer-Derived Stem Cells},
  journal = {International Journal of Molecular Sciences},
  year = {2024},
  doi = {10.3390/ijms25052876}
}
Kostenlos starten →